Drug Manufacturers General industry stocks
The Drug Manufacturers General industry has 21 US-listed companies on stockrow and is part of the Healthcare sector, with a combined market value of $4.27T. Eli Lilly and Company (LLY) is the largest at $1.18T, followed by Johnson & Johnson and AbbVie Inc.. The median Drug Manufacturers General stock trades at 24.5× trailing earnings, above the market median of 18.1×, with a median net margin of 8.27% (market: 0.45%). Median revenue growth over the last twelve months is 6.66%. 15 of the 21 pay a dividend; the median yield among payers is 2.33%.
Drug Manufacturers General medians
| Metric | Industry | Market |
|---|---|---|
| P/E | 24.5× | 18.1× |
| P/S | 3.4× | 1.9× |
| P/B | 5.0× | 1.7× |
| Price to free cash flow | 16.5× | 14.2× |
| EV/EBITDA | 13.8× | 11.0× |
| EV/Sales | 4.0× | 2.1× |
| Earnings yield | 2.98% | 1.20% |
| Free cash flow yield | 4.46% | 0.27% |
| Gross margin | 72.8% | 46.2% |
| Operating margin | 18.8% | 0.00% |
| Net margin | 8.27% | 0.45% |
| Free cash flow margin | 17.2% | 0.00% |
| Return on equity | 5.87% | 1.35% |
| Return on assets | 2.57% | 0.00% |
| Return on invested capital | 6.11% | 0.00% |
| Revenue growth (TTM) | 6.66% | 7.41% |
| EPS growth (last fiscal year) | 21.8% | 13.7% |
| Revenue growth, 5-year CAGR | 4.75% | 8.93% |
| Net income growth, 5-year CAGR | 0.00% | 0.00% |
| Debt to equity | 0.6× | 0.1× |
| Current ratio | 1.3× | 1.6× |
| Net debt to EBITDA | 1.2× | 0.6× |
| Dividend yield | 2.33% | 2.26% |
| Payout ratio | 0.6× | 0.3× |
| Market cap | $123.7B | $584.7M |
Today’s biggest moves
All 21 companies
Open in screener| LLY | Eli Lilly and Company | 1.18t | 1,257.03 | 0.43% | 42.18 | 33.53% | 49.58% | 0.53% |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 610.38b | 255.55 | 0.90% | 29.61 | 16.20% | 7.80% | 2.07% |
| ABBV | AbbVie Inc. | 500.80b | 285.42 | 0.71% | 80.63 | 9.74% | 10.39% | 2.42% |
| MRK | Merck & Co., Inc. | 358.21b | 145.95 | 0.52% | 116.76 | 4.77% | 4.64% | 2.33% |
| NVS | Novartis AG | 275.28b | 150.62 | 0.16% | 22.62 | 22.50% | 2.73% | 3.15% |
| AZN | AstraZeneca PLC | 258.50b | 165.41 | (0.76%) | 24.54 | 17.02% | 8.61% | 1.94% |
| AMGN | Amgen Inc. | 234.65b | 432.49 | (0.35%) | 26.66 | 22.95% | 9.10% | 2.30% |
| GILD | Gilead Sciences, Inc. | 195.13b | 156.19 | (0.75%) | 0.00 | (10.64%) | 5.52% | 2.08% |
| PFE | Pfizer Inc. | 167.80b | 29.58 | 0.48% | 38.92 | 6.80% | (0.21%) | 5.81% |
| NVO | Novo Nordisk A/S | 131.23b | 38.83 | (0.99%) | 9.49 | 35.47% | 13.15% | 4.63% |
| BMY | Bristol Myers Squibb Company | 123.73b | 59.71 | (1.42%) | 13.15 | 18.87% | 3.11% | 4.22% |
| GSK | GSK PLC Sponsored ADR | 98.21b | 49.55 | 1.08% | 15.44 | 14.58% | 8.72% | 3.67% |
| SNY | Sanofi | 96.03b | 40.61 | 0.79% | 21.26 | 8.22% | 21.30% | 5.97% |
| BIIB | Biogen Inc. | 34.77b | 232.65 | (1.15%) | 40.96 | 8.32% | 0.31% | — |
| OGN | Organon & Co. | 3.61b | 13.76 | 0.00% | 17.42 | 3.41% | (2.45%) | 0.58% |
| GRFS | Grifols, S.A. | 1.95b | 7.64 | 1.33% | 8.46 | 5.54% | 16.03% | 1.24% |
| AMRN | Amarin Corporation PLC | 244.36m | 11.37 | (1.73%) | 0.00 | (14.56%) | (15.10%) | — |
| NSRX | Nasus Pharma Ltd. | 37.06m | 3.18 | 0.32% | — | — | — | — |
| MIRA | MIRA Pharmaceuticals, Inc. | 27.65m | 0.63 | (4.55%) | 0.00 | 0.00% | — | — |
| SCLX | Scilex Holding Company | 19.84m | 2.83 | 0.35% | 0.00 | (1,418.45%) | (28.55%) | — |
| MDCX | Medicus Pharma Ltd | 6.34m | 3.27 | (4.66%) | 0.00 | 0.00% | — | — |